P160 Interim results of a prospective cohort study to monitor the emergence of resistance in immunocompromised non-hospitalised patients with COVID-19 who were treated with Sotrovimab in Great Britain: LUNAR study

Abstract

IntroductionImmunocompromised (IC) patients are at risk of adverse COVID-19 outcomes. The risk of treatment emergent resistance may be high in this population. This study investigated clinical and virological outcomes in...